Mesenchymal stem (stromal) cells (MSCs) are rare, multipotent progenitor cells that can be isolated and expanded from bone marrow and other tissues. Strikingly, MSCs modulate the functions of immune cells, including T cells, B cells, natural killer cells, monocyte/macrophages, dendritic cells, and neutrophils. T cells, activated to perform a range of different effector functions, are the primary mediators of many autoimmune and inflammatory diseases as well as of transplant rejection and graft-versus-host disease. Well-defined T-cell effector phenotypes include the CD4+ (T helper cell) subsets Th1, Th2, and Th17 cells and cytotoxic T lymphocytes derived from antigen-specific activation of naïve CD8+ precursors. In addition, naturally occurring and induced regulatory T cells (Treg) represent CD4+ and CD8+ T-cell phenotypes that potently suppress effector T cells to prevent autoimmunity, maintain self-tolerance, and limit inflammatory tissue injury. Many immune-mediated diseases entail an imbalance between Treg and effector T cells of one or more phenotypes. MSCs broadly suppress T-cell activation and proliferation in vitro via a plethora of soluble and cell contact-dependent mediators. These mediators may act directly upon T cells or indirectly via modulation of antigen-presenting cells and other accessory cells. MSC administration has also been shown to be variably associated with beneficial effects in autoimmune and transplant models as well as in several human clinical trials. In a small number of studies, however, MSC administration has been found to aggravate T cell-mediated tissue injury. The multiple effects of MSCs on cellular immunity may reflect their diverse influences on the different T-cell effector subpopulations and their capacity to specifically protect or induce Treg populations. In this review, we focus on findings from the recent literature in which specific modulatory effects of MSCs on one or more individual effector T-cell subsets and Treg phenotypes have been examined in vitro, in relevant animal models of in vivo immunological disease, and in human subjects. We conclude that MSCs have the potential to directly or indirectly inhibit disease-associated Th1, Th2, and Th17 cells as well as cytotoxic T lymphocytes but that many key questions regarding the potency, specificity, mechanistic basis, and predictable therapeutic value of these modulatory effects remain unanswered.

Transgenic (TG) mice expressing a high copy number of interleukin (IL)-7 cDNA under the control of the major histocomaptability complex (MHC) class II promoter display a 10–20-fold increase in total T cell numbers. Here, we show that the increase in T cell numbers in IL-7 TG mice is most apparent at the level of memory phenotype CD44^hi CD122^hi CD8⁺ cells. Based on studies with T cell receptor (TCR) TG mice crossed to IL-7 TG mice, increased levels of IL-7 may provide costimulation for TCR recognition of self-MHC ligands and thus cause naive CD8⁺ cells to proliferate and differentiate into memory phenotype cells. In addition, a marked increase in CD44^hi CD122^hi CD8⁺ cells was found in IL-7 TG IL-15⁻ mice. Since these cell are rare in normal IL-15⁻ mice, the dependency of memory phenotype CD8⁺ cells on IL-15 can be overcome by overexpression of IL-7.

In this report, the ontogeny of precursors of T cell growth factor (TCGF)-producing cells in the mouse thymus was investigated using a recently described limiting dilution microculture system. In agreement with previous studies, in the adult thymus TCGF production by cells stimulated by alloantigens was largely the property of the Lyt-2-negative subpopulation. Furthermore, when Lyt-2-negative cells were stained with monoclonal antibody GK-1.5 and sorted according to fluorescence intensity, all precursors of TCGF-producing cells were quantitatively recovered in the GK-1.5-positive subpopulation. During ontogeny, TCGF production by Lyt-2-negative thymocytes was first detectable on the 19th day of embryonic development at which time the precursor frequency was 1/10th that found in the adult thymus. As in the adult thymus, all precursors of TCGF-producing cells had the GK-1.5-positive, Lyt-2-negative phenotype. In parallel to these functional studies, the ontogeny of GK-1.5+, Lyt-2- cells was investigated. In the adult thymus, 80% of cells expressed both GK-1.5 and Lyt-2 antigens, whereas minor subpopulations of 10% and 5% (corresponding to phenotypically mature thymocytes as defined by cortisone-resistant thymocytes [CRT]) expressed GK-1.5 or Lyt-2 exclusively; 3% of cells expressed neither antigen. During ontogeny, thymocytes expressing both GK-1.5 and Lyt-2 first appeared on the 16th day of embryonic development and their proportion increased rapidly thereafter. Interestingly, the GK-1.5+, Lyt-2- subpopulation first appeared in significant numbers on day 19 in parallel with the appearance of functional TCGF activity. Taken together with our previous studies correlating cytolytic T lymphocyte precursor (CTL-P) activity with the Lyt-2+, GK-1.5- subpopulation, these results further emphasize the strict correlation between functional activity and mature surface phenotype of both embryonic and adult thymocytes.

The Ly phenotype of cells mediating skin graft rejection was determined using monoclonal anti-Lyt-1.1 and Lyt-2.1 antibodies in CBA mice that received CBA lymphoid cells from mice sensitized to C57BL/6; i.e., alloantigenic differences arising from the H-2 and non-H-2 loci. It was clear that graft rejection was due wholly to the presence of Lyt-1 cells in the inoculum and that Lyt-123 or Lyt-23 cells had no effect. Furthermore, no synergism was noted between Lyt-1 and Lyt-2 cells. In this model, both the cytotoxic T cell and cytotoxic lymphocyte precursors were shown to be Lyt-123 and these could be depleted from sensitized Lyt-1 populations that mediated graft rejection. Thus cytotoxic T cells are not responsible for skin graft rejection, but rather, this is mediated by an Lyt-1 cell. Whether this T cell is distinct from other Lyt-1 cells (T helper, T cells mediating delayed hypersensitivity) is not clear at present, but other evidence, and traditional concepts, link graft rejection and delayed type hypersensitivity as being different manifestations of the same mechanism.